Port Royal, hospital cochin
Paris, 75014, France
Location status: Recruiting
NCT Number: NCT04481321
The purpose of this study is to determine whether endometriosis and adenomyosis are progressive diseases, in terms of symptoms (pain, abnormal uterine bleeding and infertility), anatomical lesions size, and recurrences. We also aimed to address molecular questions on immune dialogues between ectopic lesions and the eutopic endometrium, auto-immunity in endometriosis and adenomyosis and the role of the microbiota in their respective pathophysiologies.
Interested in participating?
Request Info18 year–42 year
Female
Observational
Paris, 75014, France
Location status: Recruiting
Endometriosis and adenomyosis are benign gynecological conditions which affect more than 10% of women, that typically cause pain and / or infertility, thereby exerting a negative impact on the patients' quality of life.
Although the pathogenesis of endometriosis and adenomyosis are controversial, both diseases are defined by the presence of endometrial tissue outside the uterine cavity. Endometriosis is a heterogeneous disease, with three phenotypes: superficial peritoneal endometriosis (SUP), ovarian endometrioma (OMA), and deep infiltrating endometriosis (DIE) The most widely accepted pathophysiological hypothesis for endometriosis is that of the implantation of ectopic endometrial cells following peritoneal reflux. Endometriosis can be associated with adenomyosis, also heterogeneous, characterized by the infiltration of endometrial tissue into the myometrium, presenting different forms: diffuse, focal or cystic.
Due to diseases heterogeneity, the diagnosis of endometriosis and adenomyosis is difficult and affected patients are subject to a long delay for appropriate management.
We hypothesize that the disease may be progressive in terms of symptoms (pain, abnormal uterine bleeding and infertility), anatomical lesions and recurrences. Furthermore, highlighting specific clinical and molecular markers would shorten the diagnostic time.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Peripheral blood,, Vaginal and urinary swab, Endometriosis lesions,endometrial biopsies, Myometer biopsies, Peritoneal fluid, Follicular fluid biopsies
Time frame: 10 years
Composite outcome
Time frame: 10 years
Time frame: 1 year
Time frame: 3 years
Time frame: 5 years
Time frame: 7 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Contact information is provided by the study sponsor or research team.
Charles Chapron, MD
CONTACT
1 58 41 19 33 ext. +33
Laurence Lecomte, PhD
CONTACT
1 58 41 34 78 ext. +33
Assistance Publique - Hôpitaux de Paris
Other
ENDOCHAP Monocentric Cohort: Clinical and Molecular Study of Endometriosis and Adenomyosis
Acronym: ENDOCHAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06332560
Adenomyosis, Endometriosis
's-Hertogenbosch, Netherlands
View Trial DetailsNCT07265505
Abortion, Habitual, Abortion, Spontaneous
Paris, IDF, France
View Trial DetailsNCT07728695
Adenomyosis, Adnexal Diseases
Belmont, Massachusetts, United States
View Trial DetailsNCT07205614
Adenomyosis, Dysmenorrhea
Kristiansand, Agder, Norway
View Trial Details